Review the physiologic functions of aldosterone and explain how aldosterone excess and dysregulation contribute to sustained day- and night-time hypertension, nocturnal BP elevation, morning surge, BP variability, and the cumulative 24-hour BP burden that drives cardiovascular and cardiorenal organ damage.

Describe how 24-hour ABPM detects and confirms biologically meaningful BP phenotypes, including nocturnal hypertension, non- and reverse-dipping, morning surge, and high BP variability, and correlate these ABPM-detected patterns with underlying mechanisms such as RAAS activation, aldosterone excess, sodium retention, OSA, and sympathetic overactivity.

Summarize 24-hour and nocturnal BP findings from contemporary aldosterone-targeted trials (e.g., Bax24 with baxdrostat, ADVANCE-HTN with lorundrostat) and explain what these ABPM studies reveal about the impact of aldosterone synthase inhibition on 24-hour BP burden, nocturnal control, and dipping status in resistant or poorly controlled hypertension.

Relate key ABPM metrics (24-hour SBP, nocturnal SBP, dipping pattern, variability) to clinical outcomes such as CKD progression, heart failure, stroke, and mortality, and discuss how sustained BP control and more intensive targeting of aldosterone (with MR antagonists and emerging ASIs) may improve long-term cardiovascular and cardiorenal protection the spectrum of aldosterone-driven hypertension.